Paclitaxel
- Atc Codes:L01CD01
- CAS Codes:33069-62-4
- PHARMGKB ID:33069-62-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Abraxane, Ebetaxel, Novatax, Paclitaxel, Paxene (d), Taxol; Belgium: Paclitaxel, Taxol; Bulgaria: Genexol, Paclitaxel, Paclitaxin, Taxol; Czech Republic: Abraxane, Anzatax, Egilitax, Eucol, Oncotax, Paclimedac, Pacline, Paclitaxel, Paxene (d), Taxol; Denmark: Paclitaxel, Taxol; Estonia: Abraxane, Eucol, Pacline, Paclitaxel, Paxene (d), Taxol; Finland: Paclitaxel, Paclitaxin, Taxol; France: Abraxane, Mediphaxel, Paclimed, Paclitaxel, Paclivis, Paxene (d), Taxol; Germany: Abraxane, Aritaxel, Celltaxel, Neotaxan, Paclisachs, Paclitax, Paclitaxel, Paxene (d), Ribotax, Ribotaxel, Taxol, Taxomedac; Greece: Biotaxel, Oncotaxen, Ovapac, Pacline, Paclit, Paclitaxel, Paclitaxin, Paclitol, Paclixel, Pataxel, Paxene (d), Paxital, Ribotal, Taxogen, Taxol, Taxoprol, Xenius, Yewtaxan; Hungary: Abraxane, Genexol, Intaxel, Pacliner, Paclitaxel, Paxene (d), Taxol; Ireland: Abraxane, Cantaxel, Ebetaxel, Paclitaxel, Palat, Paxene (d), Taxol; Italy: Anzatax, Paclitaxel, Taxol; Latvia: Abraxane, Paxene (d); Lithuania: Paclitaxel; Luxembourg: Paxene (d), Taxol; Malta: Abraxane, Paxene (d); Netherlands: Paclitaxel, Paclitaxin, Paxene (d), Taxol; Poland: Abraxane, Egilitax, Paclimedac, Paclitaxel, Paclitaxelum, Paclitaxin, Paxene (d), Sindaxel, Taxol; Portugal: Abraxane, Paclitaxel, Paxene (d), Taxol; Romania: Abraxane, Egilitax, Onxol, Paclitaxel, Paxene (d), Sindaxel, Taxol, Xelpac; Slovakia: Abraxane, Egilitax, Eucol, Paclimedac, Paclitaxel, Paxene (d), Sindaxel, Taxol; Slovenia: Paclitaxel, Paclitaxin, Paklitaksel, Taxol; Spain: Paclitaxel, Paxene (d), Taxol; Sweden: Abraxane, Actaxel, Cantaxel, Paclitaxel, Pacovary, Paklimedica, Paklitaxel, Paklitaxomed, Taxol; UK: Abraxane, Paclitaxel.
North America
Canada: Abraxane, Paclitaxel, Taxol; USA: Abraxane, Paclitaxel, Taxol.
Latin America
Argentina: Asotax, Dalys, Drifén, Erioxal, Paclikebir, Paclitaxel, Pacliteva, Paklitaxfil, Panataxel, Tarvexol, Taxocris, Taxol, Taycovit; Brazil: Biopaxel, Evotaxel, Onxel, Paclitaxel, Parexel, Tarvexol, Taxilán, Taxol; Mexico: Aclixel, Asotax, Bristaxol, Cryoxet, Daburex, Paclisán, Praxel.
Asia
Japan: Abraxane, Paclitaxel, Taxol.
Drug combinations
Chemistry
Paclitaxel: C~47~H~51~NO~14~. Mw: 853.91. (1) Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-; (2)(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine. CAS-33069-62-4 (1993).
Pharmacologic Category
Antineoplastic Agents; Plant Alkaloids and Other Natural Products; Antimicrotubular. Taxane Derivative. (ATC-Code: L01CD01).
Mechanism of action
Paclitaxel promotes microtubule assembly, and can distort mitotic spindles, resulting in breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
Therapeutic use
Treatment of breast, non-small cell lung, and ovarian cancers. Treatment of AIDS-related Kaposi’s sarcoma.
Pregnancy and lactiation implications
Animal studies demonstrated embryotoxicity, fetal toxicity, and maternal toxicity. There are no adequate, well-controlled studies in pregnant women. Contraindicated during lactation.
Unlabeled use
Treatment of bladder, cervical, prostate, small cell lung, and head and neck cancers. Treatment of (unknown primary) adenocarcinoma.
Contraindications
Hypersensitivity to paclitaxel, polyoxyethylated castor oil, or any component of the formulation.
Warnings and precautions
Hazardous agent. Bone marrow suppression is dose-limiting toxicity. Infusion-related hypotension, bradycardia, and/or hypertension may occur. Rare but severe conduction abnormalities reported. Severe hypersensitivity reactions reported. Peripheral neuropathy may occur. Use with extreme caution in hepatic dysfunction (myelotoxicity may be worsened). Use with caution in the elderly (increased risk of toxicity). Formulations contain dehydrated alcohol (may cause adverse CNS effects).